An Open-Label, Multicenter, Phase IIIb Study of Patients with Urinary Tract Carcinoma (UTC) (STRONG): Final Analysis for Fixed-Dose Durvalumab Monotherapy (Module A)
Bladder Cancer: Guru Sonpavde, MD details STRONG study results presented at ASCO #GU21? that find fixed-dose durvalumab monotherapy safe in patients previously treated for urinary tract carcinoma. Abstract 429
Guru P. Sonpavde, MD is the Bladder Cancer Director at Dana Farber Cancer Institute. At Dana-Farber, he leads multiple cutting-edge clinical trials studying novel immunotherapy and targeted drugs to cure bladder cancer.
